The COVID-19 pandemic has forced all the stakeholders in the clinical trial ecosystem to explore decentralised trials as an alternative to conventional procedures.
GlobalData has conducted a survey to identify the biggest perceived benefits of DCTs for future users in North America, Europe, Asia Pacific (APAC) and Rest of World (RoW) regions.
An analysis of the survey results shows that the respondents in North America and Europe expect that DCTs will lead to greater participation by patients.
Click here to read full article https://www.pharmaceutical-technology.com/surveys/perceived-benefits-of-decentralised-trials-for-future-users-by-geography/
